1. Japan Stocks

  2. •

    Health technology

  3. •

    Medical specialties
Japan Lifeline Co., Ltd.

Japan Lifeline Co., Ltd.

8.70
EUR
+0.05
(+0.58%)
513.25MMarket Cap
Oct 30Next Earn
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
2026 Y
TTM
Revenue per Share
282.05
297.37
399.66
499.65
557.18
566.13
644.99
638.51
640.42
662.47
675.07
798.57
843.81
- -
Basic EPS, GAAP
-2.34
13.01
36.69
71.89
98.51
96.04
96.55
24.9
93.12
88.21
98.73
131.43
133.3
- -
Free Cash Flow per Basic Share
-22.83
10.81
-12.89
71.63
25.27
65.14
56.4
128.72
104.37
121.25
60.14
106
88.36
- -
Dividend per Share
3.12
3.12
4.23
6.24
14.66
28.76
29.06
29.11
49.17
39.04
38.95
44.49
53.11
- -
Book Value per Share
169.25
178.04
213.53
278.84
510.98
578.16
640.54
638.34
682.78
721.2
775.41
854.72
939.27
- -
Tangible Book Value per Share
167.35
176.72
211.81
272.23
503.82
571.22
634.39
632.06
664.38
690.22
744.82
827.47
916.98
- -
Basic Weighted Avg Shares
86
86
76
74
76
80
80
80
80
78
76
71
70
70
Sales/Revenue/Turnover
24,371
25,696
30,540
37,181
42,298
45,525
51,761
51,286
51,469
51,750
51,384
56,610
59,187
- -
Operating Margin (%)
5.03
7.2
12.13
20.68
25.25
23.14
20.17
20.23
19.39
20.95
21.21
21.79
21.31
- -
Depreciation Expense
640
770
795
753
953
1,176
1,264
1,525
1,611
1,566
1,471
1,779
1,656
- -
Net Income, GAAP
-202
1,124
2,804
5,350
7,478
7,723
7,748
2,000
7,484
6,891
7,515
9,317
9,350
- -
Effective Tax Rate (%)
129.21
42.54
37.88
32.76
29.55
28.49
25.67
55.95
25.46
29.59
28.94
22.51
24.46
- -
Profit Margin (%)
-0.83
4.37
9.18
14.39
17.68
16.96
14.97
3.9
14.54
13.32
14.63
16.46
15.8
- -
Working Capital
10,377
10,771
12,445
15,604
24,807
27,085
27,984
28,055
30,942
32,749
28,696
30,002
35,449
- -
LT Debt
2,698
2,188
4,207
3,644
1,608
3,655
4,867
2,745
1,751
1,117
573
213
166
- -
Total Equity
14,626
15,385
15,890
20,750
41,090
46,492
51,406
51,303
54,567
56,196
58,101
59,913
65,894
- -
Return on Invested Capital (%)
-1.59
4.47
8.59
16.61
17.65
13.63
12.63
7.13
11.63
11.86
12.02
14.72
13.99
- -
Return on Capital (%)
-0.97
4.96
11.01
18.31
18.45
14.55
13.19
3.35
12.14
11.01
12.01
14.79
14.13
- -
Return on Common Equity (%)
-1.34
7.49
17.93
29.2
24.18
17.64
15.83
3.89
14.14
12.44
13.15
15.79
14.86
- -

Capital Structure

JPY

•

in mil. unless spec.
Sep'26
Mar'26
Jun'27
ST Debt
3,560
2,900
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
166
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
70
70
70
Market Capitalization
103,073
94,145
89,257

Working Capital

JPY

•

in mil. unless spec.
Sep'26
Mar'26
Jun'27
Total Current Assets
44,824
49,046
- -
Cash, Cash Equivalents & STI
9,630
12,494
- -
Accounts Receivable, Net
14,435
14,550
- -
Inventories
19,146
20,129
- -
Total Current Liabilities
13,577
13,597
- -
Payables & Accruals
- -
- -
- -
ST Debt
3,560
2,900
- -
Deferred Revenue
- -
- -
- -

Growth Rates

JPY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
17.8%
5.17%
9.98%
Free Cash Flow
-42.82%
-2.2%
-17.51%
Net Income, GAAP
35.97%
59.93%
0.35%
Sales/Revenue/Turnover
7.08%
2.98%
4.55%
Total Cash Common Dividend
36.03%
13.58%
18.1%

Quarterly Revenue

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
56,610
2026
- -
- -
- -
- -
59,187
2027
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
131.43
2026
- -
- -
- -
- -
133.3
2027
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
44.49
2026
- -
- -
- -
- -
53.11
2027
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Keisuke Suzuki
Full Time Employees
1,304
Sector
Health technology
Industry
Medical specialties
Address
Tennoz Ocean Square Tokyo TY Japan 140-0002
IPO Date
Dec 8, 1997
Website
jll.co.jp
Similar Companies
Intuitive Surgical, Inc. (NASDAQ:ISRG)
Boston Scientific Corporation (NYSE:BSX)
Thermo Fisher Scientific Inc (NYSE:TMO)
Illumina, Inc. (NASDAQ:ILMN)
Abbott Laboratories (NYSE:ABT)
GRAIL, Inc. (NASDAQ:GRAL)
Business
Japan Lifeline Co., Ltd. manufactures, imports, distributes and sells medical devices primarily focused on cardiovascular treatments in Japan. The company offers cardiac rhythm management products including cardiac pacemakers, implantable cardioverter defibrillators, subcutaneous implantable cardioverter defibrillators, cardiac resynchronization therapy defibrillators and pacemakers, automated external defibrillators, and cardiopulmonary resuscitation support devices; electrophysiology and ablation products such as electrophysiological and ablation catheters, irrigated tip ablation catheters, endoscopic balloon ablation systems, esophageal temperature monitoring systems, internal atrial cardioversion systems, and radio-frequency transseptal needles; cardiovascular and endografting products comprising vascular grafts, thoracic stent grafts, abdominal stent grafts, and frozen elephant trunks; gastrointestinal intervention products including cholangioscopes, biliary tube stents, papillary balloon dilatation catheters, self-expandable duodenal and colonic stents, endoscopic guidewires, and radiofrequency ablation systems for liver cancer; structural heart disease intervention products such as atrial septal defect closure devices and transcatheter heart valves; and neurovascular intervention products like thrombus aspiration catheters, intravascular embolic coils, and stent retrievers. Founded in 1981 and headquartered in Shinagawa-ku, Tokyo, the company operates sales offices across Japan, manufacturing facilities including Toda Factory, Ichihara Factory, and Oyama Factory, and international subsidiaries such as JLL Malaysia Sdn. Bhd. Recent developments include a September 2024 launch of a stent retriever for neurovascular interventions; a business partnership announced in September 2025 with Heartseed to co-develop and supply a catheter delivery system for clinical trials of iPS cell-derived cardiomyocyte spheroids in regenerative medicine for severe heart failure; and a March 2025 exclusive three-year distribution agreement with Philips Japan, Ltd., effective May 1, 2025, for lead management products following a basic agreement signed December 25, 2024.